JPWO2021081407A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021081407A5
JPWO2021081407A5 JP2022523574A JP2022523574A JPWO2021081407A5 JP WO2021081407 A5 JPWO2021081407 A5 JP WO2021081407A5 JP 2022523574 A JP2022523574 A JP 2022523574A JP 2022523574 A JP2022523574 A JP 2022523574A JP WO2021081407 A5 JPWO2021081407 A5 JP WO2021081407A5
Authority
JP
Japan
Prior art keywords
alkyldiyl
peg
amino
pep
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523574A
Other languages
English (en)
Japanese (ja)
Other versions
JP7709431B2 (ja
JP2022553702A5 (https=
JP2022553702A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057167 external-priority patent/WO2021081407A1/en
Publication of JP2022553702A publication Critical patent/JP2022553702A/ja
Publication of JP2022553702A5 publication Critical patent/JP2022553702A5/ja
Publication of JPWO2021081407A5 publication Critical patent/JPWO2021081407A5/ja
Application granted granted Critical
Publication of JP7709431B2 publication Critical patent/JP7709431B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523574A 2019-10-25 2020-10-23 チエノアゼピン、イムノコンジュゲート、及びそれらの使用 Active JP7709431B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962926333P 2019-10-25 2019-10-25
US62/926,333 2019-10-25
US202062984184P 2020-03-02 2020-03-02
US62/984,184 2020-03-02
PCT/US2020/057167 WO2021081407A1 (en) 2019-10-25 2020-10-23 Thienoazepine immunoconjugates, and uses thereof

Publications (4)

Publication Number Publication Date
JP2022553702A JP2022553702A (ja) 2022-12-26
JP2022553702A5 JP2022553702A5 (https=) 2023-10-20
JPWO2021081407A5 true JPWO2021081407A5 (https=) 2023-10-20
JP7709431B2 JP7709431B2 (ja) 2025-07-16

Family

ID=73544268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523574A Active JP7709431B2 (ja) 2019-10-25 2020-10-23 チエノアゼピン、イムノコンジュゲート、及びそれらの使用

Country Status (11)

Country Link
US (2) US11654199B2 (https=)
EP (1) EP4048315B1 (https=)
JP (1) JP7709431B2 (https=)
KR (1) KR20220088901A (https=)
AU (1) AU2020369652A1 (https=)
BR (1) BR112022007719A2 (https=)
CA (1) CA3155077A1 (https=)
IL (1) IL292396A (https=)
MX (1) MX2022004875A (https=)
TW (1) TWI857167B (https=)
WO (1) WO2021081407A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CA3155077A1 (en) 2019-10-25 2021-04-29 Romas Kudirka Thienoazepine immunoconjugates, and uses thereof
WO2021081402A1 (en) * 2019-10-25 2021-04-29 Bolt Biotherapeutics, Inc. Macromolecule-supported thienoazepine compounds, and uses thereof
CN115996756A (zh) * 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
CN116234586A (zh) * 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
CN118475372A (zh) * 2021-10-29 2024-08-09 博尔特生物治疗药物有限公司 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
WO2023109944A1 (zh) * 2021-12-16 2023-06-22 映恩生物制药(苏州)有限公司 Tlr调节剂及其用途
KR20230134769A (ko) * 2022-03-15 2023-09-22 에이치엘만도 주식회사 유압 밸브 블록 및 이를 포함하는 브레이크의 구동장치
WO2024129956A1 (en) * 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
WO2026050213A1 (en) * 2024-08-27 2026-03-05 Usbolt Biotherapeutics, Inc. Tlr agonist immunoconjugates and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US723288A (en) 1901-10-26 1903-03-24 Harry South Lewis Cipher-key for cryptographic codes.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
LT1976880T (lt) 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
CA2771609C (en) 2009-08-18 2018-10-02 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック, インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
RS56793B1 (sr) 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
HUE033369T2 (en) 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
KR20240005247A (ko) 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019222676A1 (en) * 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
WO2020252254A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Macromolecule-supported aminobenzazepine compounds
AU2020291014B2 (en) 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CA3155077A1 (en) 2019-10-25 2021-04-29 Romas Kudirka Thienoazepine immunoconjugates, and uses thereof
WO2021081402A1 (en) 2019-10-25 2021-04-29 Bolt Biotherapeutics, Inc. Macromolecule-supported thienoazepine compounds, and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2020252294A5 (https=)
JP2025169338A (ja) 抗体-薬物コンジュゲートの改良製造方法
JPWO2021081407A5 (https=)
JP2683080B2 (ja) トリ‐アザ大環状化合物及びそれらの金属錯体
JP2025041725A5 (https=)
JPWO2021067242A5 (https=)
JP2021506883A (ja) ピロロベンゾジアゼピン抗体結合体
IL312845B2 (en) Extacan derivatives, charge-linkers, and their conjugates
JP2020530007A5 (https=)
JPWO2021226440A5 (https=)
HK1246773A1 (zh) 递送治疗药物的ph-敏感性的连接物
JPWO2019232449A5 (https=)
JPWO2020076996A5 (https=)
JPWO2019213445A5 (https=)
JPWO2022022508A5 (https=)
JP2023505509A (ja) ポリエチレングリコール複合薬、ならびにその調製方法およびその使用
JPWO2021081402A5 (https=)
JPWO2022246576A5 (https=)
JPWO2022272039A5 (https=)
AU2023387509A1 (en) An anti-tumor compound and use thereof
JPWO2020084115A5 (https=)
JPWO2021046112A5 (https=)
JP2023537247A (ja) ポリエチレングリコール複合薬、ならびにその調製方法およびその使用
JPWO2022204528A5 (https=)
CN120957755A (zh) 多环类药物偶联物及其制备方法和用途